Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2015

01.12.2015 | editorial

Biomarkers—hope and hype

verfasst von: Martin Filipits

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

A new generation of biomarkers has become available with the discovery of the genetic alterations such as single-base substitutions, insertions, deletions, and translocations that are responsible for the development and progression of virtually all human cancers. However, it is often difficult in clinical practice to obtain sufficient tumor material for genetic analyses. Some tumors such as advanced non-small cell lung cancer are only accessible through biopsies with frequently insufficient tumor material available for genotyping. Moreover, in many patients with advanced or progressing disease it can be challenging or even impossible to acquire tumor tissue samples. In addition, in patients treated with molecular targeted therapy, clinicians frequently search for early evidence of recurrence or mechanisms underlying resistance. In these cases, the analyses of tumor-specific genetic alterations in the serum or plasma of the patients are particularly valuable because they can provide temporal measurements of the total tumor burden as well as identify specific mutations that arise during therapy. Blood samples are more easily and frequently accessible and are therefore employed to detect tumor-specific genetic alterations. This procedure is termed “liquid biopsy” [ 1]. …
Literatur
1.
Zurück zum Zitat Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86. PubMedCrossRef Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86. PubMedCrossRef
2.
Zurück zum Zitat Heitzer E. Clinical utility of circulating tumor DNA in human cancers. Memo. 2105;8. DOI 10.1007/s12254-015-0217-5. Heitzer E. Clinical utility of circulating tumor DNA in human cancers. Memo. 2105;8. DOI 10.1007/s12254-015-0217-5.
3.
Zurück zum Zitat Hamilton G. Clinical relevance of circulating tumor cells in cancer patients. Memo. 2015;8. DOI 10.1007/s12254-015-0237-1. Hamilton G. Clinical relevance of circulating tumor cells in cancer patients. Memo. 2015;8. DOI 10.1007/s12254-015-0237-1.
4.
Zurück zum Zitat Senfter D, Mader RM. Exosomes as novel biomarkers in anticancer therapy. Memo. 2015;8. DOI 10.1007/s12254-015-0245-1. Senfter D, Mader RM. Exosomes as novel biomarkers in anticancer therapy. Memo. 2015;8. DOI 10.1007/s12254-015-0245-1.
Metadaten
Titel
Biomarkers—hope and hype
verfasst von
Martin Filipits
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0235-3